BioSpace News Archive

Initial pharmacokinetic (PK), safety, and preliminary efficacy data from Phase 1 dose-escalation portion of MasterKey-01 clinical trial to be presented

Silicon Valley tech firm brings encrypted solution for tracking Canadian developer’s 15-minute Covid19 rapid antigen test for point of care, and then at-home testing

Secure AI Labs, the healthcare data security company offering a secure, easy-to-manage, and auditable solution to track and trace the use of patient data in collaborative research, is pleased to announce its partnership with the Kidney Cancer Association to provide federated learning and data security technologies for the KCA’s Data Federation.

Delix Therapeutics, a preclinical biotech company developing novel disease-modifying therapeutics for serious psychiatric and neurological conditions, lauded a study published today in the highly-regarded scientific journal

Isofol Medical AB, hereby announces that the Board of Directors has the intention to carry out an issue of shares of approximately SEK 400 million with preferential rights for the Company’s existing shareholders.

The following is attributed to Acting FDA Commissioner Janet Woodcock , M.D. Being transparent about the results of completed clinical trials enables important advances in the development of medical products and helps ensure a safe, effective and efficient clinical research enterprise.

Ivor Macleod, Chief Financial Officer of Athersys Inc. (NASDAQ: ATHX), is scheduled to speak at the Bank of America Securities 2021 Virtual Health Care Conference on Wednesday, May 12, 2021 at 12:30 pm EDT. Following a brief corporate update, Mr. Macleod will engage in a Q & A fireside chat with a Bank of America analyst.

Cytovia Therapeutics, Inc., a biopharmaceutical company developing allogeneic “off-the-shelf” gene-edited Chimeric Antigen Receptor (CAR)-NK cells derived from induced pluripotent stem cells (iPSCs) and NK cell engager multifunctional antibodies, announced today that Stanley R. Frankel, MD FACP has been appointed as Chief Medical Officer, effective immediately.

Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced today the launch of the Lyo-Ready™ DNA LAMP Mix, specifically designed for accelerating the development of ambient temperature-stable loop-mediated isothermal amplification (LAMP) assays.

Protalix BioTherapeutics, Inc. today provided an update regarding the Complete Response Letter (CRL) received from the U.S. Food and Drug Administration (FDA) regarding the Biologics License Application (BLA) seeking accelerated approval of pegunigalsidase alfa (PRX–102) for the proposed treatment of adult patients with Fabry disease. Receipt of the CRL was announced earlier today.